Neurobiologic Insights into Major Depressive Disorder: An Update on Emerging Therapies with Novel Mechanisms of Action

Neurobiologic Insights into Major Depressive Disorder: An Update on Emerging Therapies with Novel Mechanisms of Action

On-Demand Webcast
FACULTY

Michael E. Thase, MD
Professor of Psychiatry
Perelman School of Medicine
University of Pennsylvania
Philadephia, Pennsylvania

For full faculty bios, please call 609-371-1137.

TO DOWNLOAD SLIDES CLICK HERE.

INTENDED LEARNERS

This activity is intended for psychiatrists, primary care physicians, psychologists, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES

After completing this activity, participants should be able to:

  • Outline the significant prevalence and burden of major depressive disorder (MDD) and the limitations of current pharmacotherapeutic approaches to management
  • Discuss the current understanding of MDD pathophysiology with respect to the neurobiologic pathways involved and potential therapeutic targets
  • Evaluate the clinical and pharmacologic data surrounding MDD pharmacotherapies in late-stage development, in terms of their mechanisms of action, efficacy, and safety in treatment-resistant depression
  • Discuss how these novel pharmacotherapies may expand options for evidence-based management of MDD
ACTIVITY OVERVIEW

To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: 11/30/2018
Expiration Date: 11/30/2019
Estimated time to complete: 1.25 hours

For questions regarding this educational activity, please call 609-371-1137.

ACCREDITATION INFORMATION

In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 1.25 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours.

NURSING PHARMACOLOGY HOURS

This continuing nursing educational activity awards up to 1.25 pharmacology hours.

CE INFORMATION: APA

North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content.

Instructional Level: Advanced

PLANNING COMMITTEE

The planning committee comprises Michael Thase, MD; Vladimir Maletic, MD, MS; James Cannon, PhD, MS, PA-C, CAQ-Psy, DFAAPA; Julie Carbray, PhD, FPMHNP, PMHCNS; Jon W. Draud, MD, MS; Rakesh Jain, MD, MPH; Saundra Jain, MA, PsyD, LPC; Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA; Vladimir Maletic, MD, MS; Dougles Noordsy, MD; Andrew Penn, RN, MS, NP, CNS, APRN-BC; Charles L. Raison, MD; William C. Torrey, MD; and Meaghan Benci, Raquel Gaerlan, Jennifer Ilcyn, Randy Robbin, Horacio Rodriguez, Kelly Sweeney, and Susan Yarbrough.


Independent Clinical Reviewers: 

Douglas L. Noordsy, MD
Clinical Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine; Director of Sports Psychiatry, Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California

William C. Torrey, MD
Professor and Vice Chair for Clinical Services, Dartmouth’s Geisel School of Medicine, Dartmouth-Hitchcock, Lebanon, New Hampshire


Nurse Planner: 

Andrew Penn, RN, MS, NP, CNS, APRN-BC
Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, CA; Assistant Clinical Professor, University of California, San Francisco, CA

FINANCIAL DISCLOSURE AND CONFLICTS OF INTEREST

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty reported the following:

Dr. Thase: Consultant—Acadia, Inc., Akili, Inc., Alkermes, Inc., Cerecor, Inc., Gerson Lehrman Group, Inc., Guidepoint Global, LLC, Janssen Pharmaceuticals, Inc., H. Lundbeck A/S, MedAvante, Inc., moksha8 Pharmaceuticals, Inc., Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sage Pharmaceuticals, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd.; Employment (spouse)—Peloton Advantage (does business with several pharmaceuticals); Grant/Research Support—Acadia, Inc., Agency for Healthcare Research and Quality, Alkermes, Allergan, Inc., AssureRx Health, Inc., Axome, Inc., Intracellular Inc., Janssen Pharmaceuticals, Inc., National Institute of Mental Health, Patient Centered Outcomes Research Institute; Royalties—American Psychiatric Foundation, Guilford Publications, Herald House, W.W. Norton & Company, Inc.

Dr. Carbray: Consultant—Neurocrine.

Dr. Rakesh Jain: Advisory Board—Addrenex, Alkermes, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Consultant—Addrenex, Allergan, Avanir, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Consultant (spouse)—Lilly, Otsuka, Pamlab, Sunovion; Grant/Research Support—AstraZeneca, Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau—Addrenex, Alkermes, Allergan, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, Tris Pharmaceuticals.

Dr. Saundra Jain: Advisory Board (spouse)—Addrenex, Alkermes, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Consultant—Lilly, Otsuka, Pamlab, Sunovion; Consultant (spouse)—Addrenex, Allergan, Avanir, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Grant/Research Support (spouse)—AstraZeneca, Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau (spouse)—Addrenex, Alkermes, Allergan, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, Tris Pharmaceuticals.

Dr. Raison: Consultant—Alkermes, Emory Healthcare, Novartis, Usona Institute.

Dr. Draud, Ms. Judd, Dr. Noordsy, Mr. Penn, and, Dr. Torrey have disclosed no relevant financial relationships with any commercial interests.

Ms. Benci, Ms. Gaerlan, Ms. Ilcyn, Mr. Robbin, Mr. Rodriguez, Ms. Sweeney and Ms. Yarbrough have disclosed no relevant financial relationships with any commercial interests.

UNAPPROVED AND INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the Food and Drug Administration (FDA) of the United States or European Medicines Agency (EMA). Participants are encouraged to consult the EMA-approved or FDA-approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed in this document are the opinions of the presenters and do not necessarily reflect the opinions of Imedex, LLC and/or NACCME, LLC.

HARDWARE/SOFTWARE REQUIREMENTS

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC (NACCME). All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

GRANT SUPPORT

This activity is supported by an educational grant from Alkermes Inc.